FULC vs FIP Comparison

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

FTAI Infrastructure Inc is engaged in five segments; Railroad segment, which includes eight freight railroads and one switching company that provide rail service to certain manufacturing and production facilities; the Jefferson Terminal segment, which consists of a multi-modal crude oil and refined products terminal and other related assets; The Repauno segment, which consists of a deep-water port located along the Delaware River with an underground storage cavern, a multipurpose dock, a rail-to-ship transloading system, and multiple industrial development opportunities; Power and Gas segment, which comprised Long Ridge, a multi-modal terminal located along the Ohio River; and Sustainability and Energy Transition segment, which comprised of Aleon/Gladieux, Clean Planet, and CarbonFree.